Home » Topics » BioWorld Science

BioWorld Science
RSS

Targeting PARP could fight cancer-associated virus

Jan. 20, 2022

BATF promotes lung tissue protection during acute respiratory virus infection

Jan. 20, 2022

Targeting specific behavioral immune traits of inflammation

Jan. 20, 2022

DNA-PK activates survival kinase AKT in response to DNA damage

Jan. 20, 2022

Red Bull GmbH presents dopamine reuptake inhibitors

Jan. 20, 2022

Medshine Discovery synthesizes new JAK3 inhibitors

Jan. 20, 2022

Sun Pharmaceutical Industries divulges GIPR and GLP-1 receptor dual agonists

Jan. 20, 2022

Jiangsu Hengrui Medicine and Shanghai Hengrui Pharmaceutical patent new ATR kinase inhibitors

Jan. 20, 2022

Kallyope presents new AMPK activators

Jan. 20, 2022

Nanodecoys scavenge RANKL and TNF-alpha for osteoporosis treatment

Jan. 20, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...